Difficulties can arise when only a small percentage of even a large initial cohort develop AD over the course of the study, making it problematic to detect potential effects of therapeutic interventions on outcome. One key determinant is lipophilicity. Between 1 and 6 h there was a large reduction in statin levels and is similar to the reduction in lovastatin levels in the CSF study 13 discussed earlier in this review. The detection limit of the statins was 0. Tapia-Perez JH, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Although epidemiology and preclinical statin research described in part I of this review have generally supported an adverse role of high cholesterol levels regarding AD, human studies of statins reviewed herein show highly variable outcomes, making it difficult to draw firm conclusions.
Stopping Statins May Be Associated with the Development of Parkinson Disease
Statins as Neuroprotectants: A Comparative In Vitro Study of Lipophilicity, Blood-Brain-Barrier Penetration, Lowering of Brain Cholesterol, and Decrease of Neuron Cell Death
Statins of Different Brain Penetrability Differentially Affect CSF PLTP Activity
The primary outcome was to evaluate the efficacy of simvastatin in improving the depressive symptoms. Alternatives are niacin, usually as niacinamide, red yeast rice, or garlic extract—all of which are supported by research evidence for lowering cholesterol. Fiedorowicz JG, Coryell WH. Simvastatin but not pravastatin affects sleep: